Author

Ryuji Terata

Observed name: Terata, Ryuji

Institution: Tanabe Pharma Corporation (Japan)

Observed institution: Tanabe Pharma Corporation (Japan)

OpenAlex ID: A5041990355

Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study

2020 · Takashi Wada, Masaya Inagaki, et al. · Clinical and Experimental Nephrology · 99

Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period

2017 · Takashi Kadowaki, Kazuoki Kondo, et al. · Expert Opinion on Pharmacotherapy · 25

Pharmacological and clinical profile of a novel DPP-4 inhibitor teneligliptin hydrobromide hydrate (TENELIA^|^#174;)

2013 · Maki Goda, Fumihiko Akahoshi, et al. · Folia Pharmacologica Japonica · 1

Works count: 4

Citation count: 125

H-index: 2

I10-index: 2